Refractory chronic cough (RCC), defined as a persistent cough lasting over eight weeks, affects 2% to 18% of the global population, imposing a significant physical, psychological, and economic burden[1]. Despite its widespread impact, current treatment options remain limited—many are used off-label, do not address the underlying disease pathology, and come with limited...Read the Full Article
Over 300,000 Canadians, 1.5 million Americans, and nearly 9 million people worldwide live with Type 1 Diabetes (T1D) [1,2]. Despite advancements in treatment, T1D remains a life-altering autoimmune disease requiring lifelong management. However, recent breakthroughs in immunotherapy and regenerative medicine are opening new frontiers, drawing heightened interest from pharmaceutical companies, investors, and...Read the Full Article
Gene editing technology has the potential to revolutionize the treatment of genetic diseases by directly altering DNA within cells. However, current methods face significant limitations, including low on-target editing efficiency and unintended off-target effects. These challenges underscore the urgent need for novel approaches that can overcome these barriers and more precisely target...Read the Full Article
Cognitive deficits are a core feature of numerous psychiatric and neurodegenerative disorders, affecting over 40% of individuals with major depressive disorder (MDD), 45-77% of those with schizophrenia and bipolar disorder, and millions more experiencing age-related cognitive decline [1,2]. These impairments—spanning memory, attention, and executive function—persist even in patients whose other symptoms have...Read the Full Article